Early C-reactive protein kinetics predicts immunotherapy response in non-small cell lung cancer in the phase III OAK trial.
JNCI cancer spectrum
View this publicationJNCI cancer spectrum
View this publicationEuropean urology
View this publicationMed (New York, N.Y.)
View this publicationCurrent oncology (Toronto, Ont.)
View this publicationScientific reports
View this publicationCell reports
View this publicationEuropean urology
View this publicationScience immunology
View this publicationCancers
View this publicationCurrent oncology (Toronto, Ont.)
View this publication